A Study of Nilotinib Versus Imatinib in GIST Patients
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Gastrointestinal Stromal Tumor (GIST)
DRUG: Nilotinib (AMN107)|DRUG: imatinib (STI571)
Time to Progression Free Survival (PFS), PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, up to month 37
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).